Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a ...

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a ...

More than half a million people are buying weight-loss injections online because of the “slow” rollout of the drugs by the ...

If you are considering a natural over the counter Mounjaro alternative for 2025 - we have the top 3 options for you. SAN ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

Investing in dividend stocks is a great strategy for many reasons, including the potential they offer you to significantly ...

Whether it’s Ozempic, one of the antidiabetic drugs that have gained popularity for its weight loss benefits, or a similar ...

The FDA has declared the end of the two-year shortages of Eli Lilly's Mounjaro and Zepbound — used to treat diabetes and weight loss, respectively — and has reaffirmed its decision to halt the ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the first ...